Brief: Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study Conducted At Massachusetts General Hospital
19/11/2025 13:58
Alzamend Neuro Inc ALZN.O: ALZAMEND NEURO ANNOUNCES COMPLETION OF CLINICAL PORTION OF PHASE II CLINICAL TRIAL OF AL001 "LITHIUM IN BRAIN" STUDY CONDUCTED AT MASSACHUSETTS GENERAL HOSPITAL Source text: ID:nPn3667t6a Further company coverage: ALZN.O
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview